AVISE SLE Prognostic

Specialized in
SLE Prognostic Test

AVISE^® SLE Prognostic is a 10-marker panel developed to help assess a patient’s potential risk for Thrombosis, Cardiovascular events, Lupus Nephritis and Neuropsychiatric Lupus.

The Test Includes the Following Assays

Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) show higher specificity than anti-cardiolipin assays. In 3-10% of APS patients, β2 GP1 antibody may be the only positive test. Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) IgA are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.

*Note these markers are included and reported with AVISE CTD and will not be repeated when ordered with AVISE CTD

Clinical Utility

AVISE SLE Prognostic Test Report

Sample Test Report

References:

1. Akhter E, et al. Anti-C1q antibodies have higher correlation with fl ares of lupus nephritis than other serum markers. Lupus. 2011.

2. Orbai A-M, et al. Anti-C1q Antibodies in Systemic Lupus Erythematosu. Lupus. 2015.

3. Akhter E, et al. Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus. Journal of Rheumatism. 2013.

You deserve quality test results you can trust. Order your AVISE Testing Starter Kit today!

To order your test kits please fill out the information below.

Contact Representative

First Name Last Name

Email Address Confirm Email Address

Phone Number(Required)

Preferred Method of Contact

Practice Name

Provider's Address(Required)

Street Address Address Line 2 City State ZIP Code

Reason For Contacting Us

How May We Help You?

This field is hidden when viewing the form

Source

Email

This field is for validation purposes and should be left unchanged.